What are the manufacturers of nintedanib?

Nintedanib (Nintedanib) is an oral anti-fibrotic drug mainly used to treat idiopathic pulmonary fibrosis (IPF) and certain types of lung diseases. Its mechanism of action is mainly by inhibiting multiple tyrosine kinases, intervening in the fibrosis process, reducing the degree of fibrosis in lung tissue, thereby delaying the progression of the disease. The clinical effectiveness and safety of nintedanib have been verified by multiple large-scale clinical trials and have been widely recognized.

Ofev (Ofev) is the original research product of nintedanib, produced by Bayer in Germany, and is the first brand-name drug approved for marketing. Vegat has obtained marketing approval in many countries and regions, including China, Europe, the United States, Türkiye and India. The main packaging specifications of this drug are 100mg and 150mg. Each box usually contains 30 or 60 pills, and the price range is usually between more than 4,000 to 5,000 yuan. It is worth noting that nintedanib has been included in the reimbursement scope of Class B medical insurance in China, which provides financial support to patients and significantly improves its accessibility. However, the specific price of overseas drugs may vary due to exchange rate fluctuations.

In the international market, especially in India and Southeast Asia, some pharmaceutical companies have also begun to produce generic versions of nintedanib. These generic drugs are mainly produced by BDR Company, Grandmark Pharmaceuticals, Laos ASEAN Pharmaceuticals and other companies. The generic drugs of these companies have certain cost advantages and usually have lower prices, which is undoubtedly an important treatment option for some patients with heavy financial burdens. Although the ingredients of generic drugs are basically similar to those of brand-name drugs, patients still need to be cautious when choosing due to differences in production processes and quality control.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib